Andon Health Co Ltd (002432) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Andon Health Co Ltd stock ¥63.13, price ¥52.20, upside +20.9%, quality 43 out of 100. Rating: undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥5.25 – ¥90.78 · fair‑value band ¥47.35 – ¥78.91 · the ¥52.20 price screens below the ¥63.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Andon Health Co in your weekly email
Every Wednesday you see whether Andon Health Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Andon Health Co., Ltd. engages in the research and development, production, and sales of health electronics and smart hardware products in China and internationally.
Andon Health Co., Ltd. was founded in 1995 and is based in Tianjin, China.
Stock analysis
Andon Health Co Ltd (002432) currently trades at ¥52.20, while our model-based Fair Value estimate is ¥63.13, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥132.46 per share, and 7 of the 12 models we run sit above the ¥52.20 price.
Bear case: the Asset-Based group reads lowest at ¥9.56, and 5 of the 12 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥47.35 (bear) to ¥78.91 (bull), the price of ¥52.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Andon Health Co Ltd reported revenue of 1.4B CNY in FY2025 versus 2.4B CNY in FY2021, a compound −13.1%/yr. Reported net income was 2.3B CNY in FY2025, compounding +25.7%/yr from FY2021.
Key figures
Market cap 24.3B CNY (≈ $3.6B) Mid · P/E ratio 5.0 · P/S ratio 8.30 · EPS (TTM) ¥10.44 · Dividend yield 3.2% · Return on equity 19.5% · Return on assets (EBIT) 24.8% (5-year average) · Operating margin −47.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 21%, 002432 screens cheaper than that median.
Fair Value models
Bear¥47.35Fair Value ¥63.13Bull¥78.91
Price ¥52.20 · Upside +20.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥7.51 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.8%
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+57.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+54.2%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.54.2% vs 63.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → −22%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+20.9% · Top 25%
Profitability
Return on equity (12 months)19.5% · Top 25%
Return on assets7.7% · Above median
Net margin (12 months)166.0% · Top 25%
Operating margin (12 months)−47.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−11.0% · Bottom 25%
Dividend yield (12 months)3.2% · Top 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Andon Health Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002432
Frequently asked questions
Is Andon Health Co Ltd (002432) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥63.13 versus a price of ¥52.20, about +21% upside (undervalued).
What is the fair value of 002432?
Our model-based fair value for Andon Health Co Ltd is ¥63.13 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥52.20.
What is the quality score of 002432?
Andon Health Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Andon Health Co Ltd (002432)?
Our model-based price target is the fair value of ¥63.13 (as of Nov 7, 2026) from 12 valuation models. Cautious scenario ¥47.35, optimistic scenario ¥78.91. It is a calculation from audited fundamentals, not an analyst target.
What is the Andon Health Co Ltd stock forecast for 2026?
Our models put fair value at ¥63.13, about +21% upside versus a price of ¥52.20 (undervalued). Cautious scenario ¥47.35, optimistic scenario ¥78.91. The calculation is refreshed regularly with new filings.
What is the revenue of Andon Health Co Ltd (002432)?
Andon Health Co Ltd reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Nov 7, 2026).
Does Andon Health Co Ltd pay a dividend?
Andon Health Co Ltd currently shows a dividend yield of 3.16% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Andon Health Co Ltd (002432) and when is the ex-dividend date?
Andon Health Co Ltd pays a dividend of ¥1.65 per share a year, a dividend yield of 3.2%. The last ex-dividend date was Jun 3, 2026. A dividend has been paid every year since 2021. The payout ratio is 15.8% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Andon Health Co Ltd (002432)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Andon Health Co Ltd it is ¥63.13 per share (as of Nov 7, 2026), against a price of ¥52.20. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Andon Health Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 002432 trades below its calculated fair value: price ¥52.20, fair value ¥63.13, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002432?
No. The price is what the market pays today (¥52.20); the fair value is what the company's own numbers justify (¥63.13). For Andon Health Co Ltd the two are ¥10.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Andon Health Co Ltd worth?
The market values Andon Health Co Ltd at about 24.3B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥52.20; our models calculate a fair value of ¥63.13 per share.
What do the bullish and bearish scenarios say about 002432?
Our models span a range for Andon Health Co Ltd: cautious scenario ¥47.35, base ¥63.13, optimistic ¥78.91 per share (as of Nov 7, 2026, price ¥52.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002432?
Andon Health Co Ltd trades at a price-to-earnings ratio of 5.0 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥63.13 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 16.5. Other multiples: P/B 0.2, P/S 3.2.
How solid is the balance sheet of Andon Health Co Ltd (002432)?
Balance-sheet figures for Andon Health Co Ltd (as of Nov 7, 2026): return on equity 19.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 002432 from its 52-week high?
Andon Health Co Ltd trades at ¥52.20, about 43% below its 52-week high of ¥90.78 and 34% above the low of ¥39.06 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥63.13 is for.
Which stocks are comparable to Andon Health Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Andon Health Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥52.20, calculated fair value ¥63.13 (+21%), Quality Score 43/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002432 calculated?
We run Andon Health Co Ltd through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥63.13 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Andon Health Co Ltd currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Andon Health Co Ltd (002432)?
The closing price on Nov 6, 2026 was ¥52.20. Our model-based fair value is ¥63.13, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Andon Health Co Ltd right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Andon Health Co Ltd
How large is the market capitalisation of Andon Health Co Ltd (002432)?
The market capitalisation of Andon Health Co Ltd is 24.3B CNY (≈ $3.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Andon Health Co Ltd (002432)?
The price-to-sales ratio of Andon Health Co Ltd is 8.30 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Andon Health Co Ltd (002432)?
Earnings per share at Andon Health Co Ltd are ¥10.44 (price ÷ EPS = P/E 5.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Andon Health Co Ltd (002432)?
The dividend yield of Andon Health Co Ltd is 3.2% (payout 15.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Andon Health Co Ltd (002432)?
The return on equity (ROE) of Andon Health Co Ltd is 19.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Andon Health Co Ltd (002432)?
On an EBIT basis the return on assets of Andon Health Co Ltd is 24.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Andon Health Co Ltd (002432)?
The operating margin of Andon Health Co Ltd is −47.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Andon Health Co Ltd (002432)?
Revenue at Andon Health Co Ltd is growing −11.0% versus a year earlier (3y avg +17.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Andon Health Co Ltd (002432)?
Earnings per share at Andon Health Co Ltd are growing +340% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Andon Health Co Ltd (002432) generate?
The free cash flow of Andon Health Co Ltd is −431M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Andon Health Co Ltd (002432) carry?
The net debt of Andon Health Co Ltd is 763M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Andon Health Co Ltd in the live analysis
One click puts Andon Health Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026